Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 9/20 | 0.46 |
| ▸ | BCHE | P06276 | 9/20 | 0.46 |
| ▸ | PTPRF | P10586 | 4/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190532 | 1.00 | CAPN1 (0.51) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2190540 | 1.00 | CAPN1 (0.51) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2191049 | 0.93 | CAPN1 (0.47) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2191053 | 0.93 | CAPN1 (0.47) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2191042 | 0.93 | CAPN1 (0.47) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2195030 | 0.83 | CA12 (0.55) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2195027 | 0.83 | CA12 (0.55) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2195033 | 0.83 | CA12 (0.55) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2190737 | 0.81 | CA12 (0.52) | CAPN1CA12CA9ACHEBCHE | |
| SCHEMBL2190732 | 0.81 | CA12 (0.52) | CAPN1CA12CA9ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180271820-A1 | METHODS OF TREATING HEART FAILURE | RAJASEKHAR VIJAYKUMAR (US) | 2018-09-27 | — | — | US | disclosed |
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | RAJASEKHAR VIJAYKUMAR (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2521447-B1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9289503-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8969354-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2521447-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011085211-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | FH, FABP3, HMGCR | CAPN1 1670/4885CA12 1911/4885CA9 1354/4885 |
| US-20180271820-A1 | METHODS OF TREATING HEART FAILURE | FABP3, FH, TNNI3 | CAPN1 3507/4885CA12 1902/4885CA9 1612/4885 |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CAPN1 1266/4885CA12 2992/4885CA9 2497/4885 |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CAPN1 1266/4885CA12 2992/4885CA9 2497/4885 |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CAPN1 1266/4885CA12 2992/4885CA9 2497/4885 |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CAPN1 1266/4885CA12 2992/4885CA9 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.